Articles by Kamel Abou Hussein, MD Foundations of Metastatic TNBC: Biology, Prognosis, and the Treatment Paradigm By Tiffany A. Traina, MD, Kamel Abou Hussein, MD, Neil Iyengar, MD, Irene Morae Kang, MD, Paolo Tarantino, MD, Fengting Yan, MD, PhD, FACP Published: June 30th 2026 | Updated: June 30th 2026 The panel grounds the discussion in the biology and natural history of metastatic triple-negative breast cancer, framing it as a high-proliferation subtype prone to rapid resistance, in which the first-line setting offers an important opportunity to influence outcomes. Panelists outline a biomarker-driven treatment algorithm stratified by PD-L1 status, germline BRCA status, and prior early-stage therapy, touching on immune checkpoint inhibition, PARP inhibitors, platinum-based chemotherapy, and the role of antibody-drug conjugates across lines of therapy.
Clinicians debate sequencing breast cancer ADCs, weighing back‑to‑back use vs chemo breaks, and managing ILD, nausea, fatigue, cardiotoxicity.
How doctors sequence ADCs, pick the best first option, and manage T-DXd ILD, nausea and fatigue in metastatic breast cancer.
ASCENT-04 shows SG plus pembrolizumab boosts PFS without extra toxicity in PD-L1+ TNBC, while trials test IO for PD-L1− disease.
New trials redefine HER2 ultra-low disease, guiding when to use T-DXd vs oral chemo and emerging Trop-2 ADC options.
DB-06 reshapes HER2 testing with ultra-low disease, guiding T-DXd timing and comparing Trop-2 ADC options by toxicity and survival data.
New first-line TDxd plus pertuzumab reshapes HER2+ metastatic care, doubling PFS and sparking debate on maintenance and CNS control.
Explore risk‑adapted T‑DXd use in early HER2+ breast cancer—who benefits, how to sequence therapy, and ILD monitoring hurdles.
Emerging trials show trastuzumab deruxtecan boosts pCR and disease-free survival in early HER2-positive breast cancer, reshaping neoadjuvant/adjuvant care with ILD monitoring.
Unmet Needs and Future Outlook for HER2-Targeted Therapies By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.
Exciting New Data for TNBC Therapies By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.
Disease State Information on TNBC By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how molecular characterization and novel agents are redefining the management of TNBC.
Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how HER2-low and HER3-directed therapies are expanding precision treatment opportunities in metastatic breast cancer.
Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how newer HER2-targeted therapies show promise for CNS disease control and broader metastatic management.
Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how thoughtful sequencing of HER2-targeted agents maximizes benefit and extends survival in metastatic settings.
Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.
First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..
The Role of ADCs in Different Subgroups By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.
Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.
Background Information on Targeted Therapies in Breast Cancer By Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.
